

Usefulness of Ergothioneine

Namika Yoshida, Konomi Ide, Marika Tanaka, Kurumi Mori, Mitsuki Ueda, Azu Tanaka, Minori Yamada and Susumu Tanaka*

Department of Nutrition Science, University of Nagasaki, Siebold, Japan

***Corresponding author:** Susumu Tanaka, Department of Nutrition Science, University of Nagasaki, Siebold, Nagasaki 851-2195, Japan

ARTICLE INFO

Received: 📅 July 03, 2025

Published: 📅 July 08, 2025

Citation: Namika Yoshida, Konomi Ide, Marika Tanaka, Kurumi Mori, Mitsuki Ueda, Azu Tanaka, Minori Yamada and Susumu Tanaka. Usefulness of Ergothioneine. Biomed J Sci & Tech Res 62(4)-2025. BJSTR. MS.ID.009764.

Introduction

Ergothioneine (EGT) is a hydrophilic sulfur-containing amino acid discovered by Tanret in 1909 in the ergot fungus [1]. In addition to *Pseudomonas aeruginosa*, other mushrooms such as shiitake, eringi, and tamogi mushrooms [2-4], yeasts such as *Pichia pastoris* and *Rhodotorula toruloides* [5,6], and bacteria such as *Mycobacterium smegmatis* and *Mycobacterium tuberculosis* [7,8] are also reported to be able to synthesize EGT based on cysteine and histidine [9]. On the other hand, the human body cannot biosynthesize EGT; therefore the concentration of EGT in the body is maintained at a constant level through dietary intake of EGT [10]. EGT exists as thionic and thiol tautomers, with the thionic form predominating at physiological pH [11]. No rapid reaction with superoxide or hydrogen peroxide, which are reactive oxygen species (ROS), and stable under oxidative stress [12]. EGT works independently of oxidative defense systems in the body, such as superoxide dismutases and glutathione peroxidase, and because it is a thione body, it exhibits strong antioxidant activity that can remove hydroxyl radicals and singlet oxygen, which existing defense systems in the body cannot handle. Its potent removal of reactive oxygen species is 3~30 times higher than that of glutathione, an antioxidant present in the body, making EGT a functional ingredient that strongly inhibits oxidative damage to cells [13].

Cellular uptake of EGT requires the specific transporter Solute carrier family 22, member 4 (SLC22A4) [14], and through SLC22A4, EGT has a tendency to accumulate in organs susceptible to oxidative stress, such as liver, kidney and spleen [11]. Furthermore, SLC22A4

uptake is directional, promoting intracellular accumulation of EGT but not extracellular efflux, allowing EGT to be retained in the body for long periods of time [10]. EGT taken into cells by SLC22A4 is further transferred to mitochondria, where it binds to and activates 3-mercaptopyruvate sulfurtransferase (MPST), enhancing mitochondrial function and increasing intracellular antioxidant capacity [15]. On the other hand, the mechanism of EGT efflux from the cells has not been clarified.

In recent years, diverse physiological effects of EGT have been reported, affecting various parts of the body. The following is a summary of reports on the effects of EGT reported to date. In the skin, EGT has potent antioxidant and cytoprotective effects; it suppresses ultraviolet (UV)-B-derived oxidative stress and inflammatory cytokines (IL-6, TNF- α , etc.), thereby reducing the melanin index and preventing UV-induced spots [16,17]. EGT can also directly remove free radicals and protect skin cells from ROS [18].

In the musculoskeletal system, EGT has been reported to improve age-related sarcopenia and muscle performance by directly binding to MPST in mitochondria, thereby enhancing mitochondrial respiratory capacity (the ability to break down organic matter with oxygen and synthesize ATP) [15,19]. EGT also inhibits the progression of osteoarthritis by markedly reducing the expression of the inflammatory factor IL-1 β [20]. In the respiratory and cardiovascular systems, EGT has been shown to protect lung epithelial cells from oxidative stress, which may contribute to the prevention of chronic obstructive pulmonary disease by suppressing the expression of inflammatory factors such as TNF- α and IL-8 [21,22]. Furthermore, it has been suggested

that EGT may reduce the risk of cardiovascular diseases such as atherosclerosis by preventing the destruction of nitric oxide by superoxide anion radicals (O₂⁻), thereby maintaining nitric oxide-dependent endothelial function and preventing vascular endothelial dysfunction [23-25]. In the nervous system, it has been reported that inhibition of amyloid- β accumulation may inhibit the onset of Alzheimer's disease [26].

However, it has been reported to be involved in an increased risk of Alzheimer's disease [27], so further reports are awaited. In Parkinson's disease, reducing oxidative stress inhibits alpha-synuclein aggregation and contributes to the prevention of disease onset [28]. EGT has also been suggested to serve as a potential therapeutic strategy in the study of brain aging because it restores aging cells by improving mitochondrial function [29]. In addition, in relation to psychiatric disorders, since reduced blood EGT levels have been reported in patients with mental distress [30], EGT may act as a neurotransmission stimulator, stimulating neurogenesis [31] and alleviating psychiatric symptoms. In the gastrointestinal and endocrine systems, EGT has been shown to suppress inflammatory responses and maintain the gastrointestinal environment in patients with radiation gastroenteritis [32]. In ulcerative colitis, it also suppresses CD4-positive T cells and macrophages, thereby restoring the intestinal mucosa and promoting the resolution of inflammation [33]. In the liver, anti-inflammatory and antioxidant effects have been reported, as well as reduction of iron overload-induced hepatocellular injury due to chelation of iron by EGT [34-42]. It has also been reported to have antithyroid effects and to inhibit diabetic encephalopathy caused by hyperglycemia [43,44].

In the urinary system, EGT has been reported to protect cells and reduce renal dysfunction by suppressing oxidative stress and inflammatory cytokines such as NF- κ B, TNF- α and IL-1 β in the kidney [45,46]. It has also been suggested that SLC22A4 expression contributes to the suppression of stromal fibrosis under oxidative stress in diabetic kidney disease [47]. In the reproductive system, EGT administration is known to protect sperm from ROS, improve sperm motility, and increase fertilization rate by improving egg quality [48-50]. In addition, its involvement in obstetric and gynecological disorders such as endometriosis and preeclampsia has been reported, suggesting that EGT may be effective as a therapeutic agent [51,52]. In the immune system, EGT acts on both innate and acquired immunity and acts as an immune modifier by regulating macrophage M1/M2 polarity to maintain an appropriate immune response while suppressing excessive inflammatory responses [53,54]. Thus, EGT has potent antioxidant and anti-inflammatory properties and is being investigated as a potential therapeutic agent for a variety of diseases. In the developmental and reproductive systems, the effects of EGT in fertilized eggs and chorionic villi have been reported [55,56], but the significance of EGT in the endometrium is unknown.

We were the first in the world to show that SLC22A4 is up-regulated in decidualization, which is essential differentiation for embryo implantation, in endometrial stromal cells, and that EGT promotes placentalization by enhancing IGFBP1 secretion from endometrial stromal cells [57]. Finally, blood EGT levels derive not only from dietary intake but also from synthesis by fungi and gut microbiota [10,58]. On the other hand, it has also been suggested that *Helicobacter pylori* and intestinal bacteria in the stomach may metabolize dietary EGT and contribute to the production of trimethylamine N-oxide, a metabolite linked to disease [59]. This suggests that EGT produced by gut bacteria may also influence health. In mentally stressed rats, levels of *Lactobacillus reuteri*, a gut bacterium, are elevated, and this is associated with increased EGT production [60]. Oral administration of EGT to such rats reduces stress. This suggests that microbiota-derived EGT may have a role not only in stress reduction but also in preventing miscarriage, a condition closely linked to stress—particularly that caused by disturbances in the autonomic nervous system.

References

1. Tanret C (1909) Sur une base nouvelle retiree du seigle ergote, l'ergothioneine. Rend Acad Sci 149: 222-224.
2. Stanley L (1978) Expanded-role' nursing hits the hospitals. RN 41: 54-59.
3. Yen M T, Y H Chang, S J Huang, M C Cheng, J L Mau (2018) Extraction of ergothioneine from *pleurotus eryngii* and *p. Citrinopileatus* (agaricomycetes) and preparation of its product. Int J Med Mushrooms 20(4): 381-392.
4. Sato M, D Torigoe, Y Kinoshita, M Cyuman, C Toda, et al. (2025) Long-term intake of tamogi-take mushroom (*pleurotus cornucopiae*) mitigates age-related cardiovascular dysfunction and extends healthy life expectancy. NPJ Aging 11(1): 1.
5. Cheng B, K Yu, X Weng, Z Liu, X Huang, et al. (2024) Impact of cell wall polysaccharide modifications on the performance of pichia pastoris: Novel mutants with enhanced fitness and functionality for bioproduction applications. Microb Cell Fact 23: 55.
6. Liu K, G Xiang, L Li, T Liu, J Ke, et al. (2024) Engineering non-conventional yeast rhodotorula toruloides for ergothioneine production. Biotechnol Biofuels Bioprod 17: 65.
7. Genghof D S, O Van Damme (1968) Biosynthesis of ergothioneine from endogenous hercynine in mycobacterium smegmatis. J Bacteriol 95(2): 340-344.
8. Yelamanchi S D, S T Arun Kumar, A Mishra, T S Keshava Prasad, A Surolia (2022) Metabolite dysregulation by pranlukast in mycobacterium tuberculosis. Molecules 27(5): 1520.
9. Melville D B, W H Horner, C C Otken, M L Ludwig (1955) Studies on the origin of ergothioneine in animals. J Biol Chem 213(1): 61-68.
10. Paul B D, S H Snyder (2010) The unusual amino acid l-ergothioneine is a physiologic cytoprotectant. Cell Death Differ 17(7): 1134-1140.
11. Tang R M Y, I K Cheah, T S K Yew, B Halliwell (2018) Distribution and accumulation of dietary ergothioneine and its metabolites in mouse tissues. Sci Rep 8(1): 1601.
12. Akanmu D, R Cecchini, O I Aruoma, B Halliwell (1991) The antioxidant action of ergothioneine. Arch Biochem Biophys 288(1): 10-16.

13. Franzoni F, R Colognato, F Galetta, I Laurenza, M Barsotti, et al. (2006) An in vitro study on the free radical scavenging capacity of ergothioneine: Comparison with reduced glutathione, uric acid and trolox. *Biomed Pharmacother* 60(8): 453-457.
14. Kato Y, Y Kubo, D Iwata, S Kato, T Sudo, et al. (2010) Gene knockout and metabolome analysis of carnitine/organic cation transporter octn1. *Pharm Res* 27(5): 832-840.
15. Sprenger H G, M J Mittenbuhler, Y Sun, J G Van Vranken, S Schindler, et al. (2025) Ergothioneine controls mitochondrial function and exercise performance via direct activation of mpst. *Cell Metab* 37(4): 857-869.
16. Obayashi K, K Kurihara, Y Okano, H Masaki, D B Yarosh (2005) L-ergothioneine scavenges superoxide and singlet oxygen and suppresses tnfr-alpha and mmp-1 expression in uv-irradiated human dermal fibroblasts. *J Cosmet Sci* 56(1): 17-27.
17. Hanayama M, K Mori, T Ishimoto, Y Kato, J Kawai (2024) Effects of an ergothioneine-rich *pleurotus* sp. On skin moisturizing functions and facial conditions: A randomized, double-blind, placebo-controlled trial. *Front Med (Lausanne)* 11: 1396783.
18. Dong K K, N Damaghi, J Kibitel, M T Canning, K A Smiles, et al. (2007) A comparison of the relative antioxidant potency of l-ergothioneine and idebenone. *J Cosmet Dermatol* 6(3): 183-188.
19. Petrovic D, L Slade, Y Paikopoulos, D D Andrea, N Savic, et al. (2025) Ergothioneine improves healthspan of aged animals by enhancing cgpdh activity through cse-dependent persulfidation. *Cell Metab* 37(2): 542-556.
20. Wang Z, J Ma, Z Miao, Y Sun, M Dong, et al. (2023) Ergothioneine inhibits the progression of osteoarthritis via the sirt6/nf-kappab axis both *in vitro* and *in vivo*. *Int Immunopharmacol* 119: 110211.
21. Rahman I, P S Gilmour, L A Jimenez, S K Biswas, F Antonicelli, et al. (2003) Ergothioneine inhibits oxidative stress- and tnfr-alpha-induced nf-kappa b activation and interleukin-8 release in alveolar epithelial cells. *Biochem Biophys Res Commun* 302(4): 860-864.
22. Rahman I, I Kilty (2006) Antioxidant therapeutic targets in copd. *Curr Drug Targets* 7(6): 707-720.
23. Martin K R (2010) The bioactive agent ergothioneine, a key component of dietary mushrooms, inhibits monocyte binding to endothelial cells characteristic of early cardiovascular disease. *J Med Food* 13(6): 1340-1346.
24. Gokce G, M Z Arun (2014) Ergothioneine produces relaxation in isolated rat aorta by inactivating superoxide anion. *Eur Rev Med Pharmacol Sci* 18(21): 3339-3345.
25. Gokce G, M Z Arun, E Ertuna (2018) Ergothioneine prevents endothelial dysfunction induced by mercury chloride. *Exp Ther Med* 15(6): 4697-4702.
26. Wijesinghe P, C A Whitmore, M Campbell, C Li, M Tsuyuki, et al. (2023) Ergothioneine, a dietary antioxidant improves amyloid beta clearance in the neuroretina of a mouse model of alzheimer's disease. *Front Neurosci* 17: 1107436.
27. Cao D, Y Zhang, S Zhang, J Li, Q Yang, et al. (2024) Risk of alzheimer's disease and genetically predicted levels of 1400 plasma metabolites: A mendelian randomization study. *Sci Rep* 14(1): 26078.
28. Gao W, Y Wang, F Wang, X Wu, F Lu, et al. (2025) Ergothioneine exerts neuroprotective effects in parkinson's disease: Targeting alpha-synuclein aggregation and oxidative stress. *Food Res Int* 201: 115590.
29. Jones C G (1997) Chlorhexidine: Is it still the gold standard? *Periodontol* 2000 15: 55-62.
30. Sotgia S, A A Mangoni, S Zoroddu, B Di Lorenzo, A Zinellu, et al. (2024) Higher scores of the kessler psychological distress scale (k10) are associated with lower serum ergothioneine and higher serum asymmetric dimethyl-l-arginine concentrations in a cohort of middle-aged and older adults. *Clin Nutr ESPEN* 64: 107-113.
31. Shi C, S Asaba, S Nakamura, T Matsui (2025) Ergothioneine stimulates ca(2+)-mediated brain-derived neurotrophic factor expression in ne-4c nerve cells. *ACS Omega* 10(7): 7004-7012.
32. Liu Y, C Wang, R Liu, M Zhao, X Ding, et al. (2023) Adhesive ergothioneine hyaluronate gel protects against radiation gastroenteritis by alleviating apoptosis, inflammation, and gut microbiota dysbiosis. *ACS Appl Mater Interfaces* 15(16): 19833-19846.
33. Gao Y, B Zhou, H Zhang, L Chen, X Wang, et al. (2022) L-ergothioneine exhibits protective effects against dextran sulfate sodium-induced colitis in mice. *ACS Omega* 7(25): 21554-21565.
34. Salama S A, H A Omar (2021) Modulating nf-kappab, mapk, and pi3k/akt signaling by ergothioneine attenuates iron overload-induced hepatocellular injury in rats. *J Biochem Mol Toxicol* 35(5): e22729.
35. Tang Y, Y Masuo, Y Sakai, T Wakayama, T Sugiura, et al. (2016) Localization of xenobiotic transporter octn1/slc22a4 in hepatic stellate cells and its protective role in liver fibrosis. *J Pharm Sci* 105(5): 1779-1789.
36. Shu G, X Lei, G Li, T Zhang, C Wang, et al. (2023) Ergothioneine suppresses hepatic stellate cell activation via promoting foxa3-dependent potentiation of the hint1/smad7 cascade and improves ccl (4)-induced liver fibrosis in mice. *Food Funct* 14(23): 10591-10604.
37. Mao Y, Z Xie, X Zhang, Y Fu, X Yu, et al. (2025) Ergothioneine ameliorates liver fibrosis by inhibiting glycerophospholipids metabolism and tgfr-beta/smds signaling pathway: Based on metabolomics and network pharmacology. *J Appl Toxicol* 45(3): 514-530.
38. Lv X, C Nie, Y Shi, Q Qiao, J Gao, et al. (2024) Ergothioneine ameliorates metabolic dysfunction-associated steatotic liver disease (masld) by enhancing autophagy, inhibiting oxidative damage and inflammation. *Lipids Health Dis* 23(1): 395.
39. Kawano H, H Murata, S Iriguchi, T Mayumi, T Hama (1983) Studies on ergothioneine. Xi. Inhibitory effect on lipid peroxide formation in mouse liver. *Chem Pharm Bull (Tokyo)* 31(5): 1682-1687.
40. Kawano H, K Cho, Y Haruna, Y Kawai, T Mayumi, et al. (1983) Studies on ergothioneine. X. Effects of ergothioneine on the hepatic drug metabolizing enzyme system and on experimental hepatic injury in rats. *Chem Pharm Bull (Tokyo)* 31: 1676-1681.
41. Dare A, M L Channa, A Nadar (2021) L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia. *Can J Physiol Pharmacol* 99(11): 1137-1147.
42. Cheah I K, R Tang, P Ye, T S Yew, K H Lim, et al. (2016) Liver ergothioneine accumulation in a guinea pig model of non-alcoholic fatty liver disease. A possible mechanism of defence? *Free Radic Res* 50(1): 14-25.
43. Song T Y, N C Yang, C L Chen, T L V Thi (2017) Protective effects and possible mechanisms of ergothioneine and hispidin against methylglyoxal-induced injuries in rat pheochromocytoma cells. *Oxid Med Cell Longev* 2017: 4824371.
44. Wilson M L, G D Mc (1949) Antithyroid activity of ergothioneine. *Am J Physiol* 156(3): 377-380.
45. Dare A, M L Channa, A Nadar (2021) L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat

- model by activating nrf2 antioxidant pathway. *Biomed Pharmacother* 141: 111921.
46. Salama S A, G M Abd Allah, A M Mohamadin, M M Elshafey, H S Gad (2021) Ergothioneine mitigates cisplatin-evoked nephrotoxicity via targeting nrf2, nf-kappab, and apoptotic signaling and inhibiting gamma-glutamyl transpeptidase. *Life Sci* 278: 119572.
 47. Makiishi S, K Furuichi, Y Yamamura, K Sako, Y Shinozaki, et al. (2021) Carnitine/organic cation transporter 1 precipitates the progression of interstitial fibrosis through oxidative stress in diabetic nephropathy in mice. *Sci Rep* 11: 9093.
 48. Strzezek R, M Koziorowska Gilun, M Kowalowka, J Strzezek (2009) Characteristics of antioxidant system in dog semen. *Pol J Vet Sci* 12(1): 55-60.
 49. Mayumi T, H Kawano, Y Kawai, T Hama (1984) Studies on ergothioneine. Ix. Ergothioneine stimulates mouse spermatozoa and fertilization in vitro: (ergothioneine/fertilization/acrosome reaction/sperm penetration). *Dev Growth Differ* 26: 563-569.
 50. Cuyan K, N Baspinar, M N Bucak, P P Akalin (2011) Effects of cysteine and ergothioneine on post-thawed merino ram sperm and biochemical parameters. *Cryobiology* 63(1): 1-6.
 51. Liu L, J Yin, Y Liu, B Li, S Kang, et al. (2024) Causal effects of genetically determined circulating metabolites on endometriosis: A mendelian randomization study. *Medicine (Baltimore)* 103(47): e40690.
 52. Kenny L C, S Consortium, L W Brown, P Ortea, R Tuytten, et al. (2023) Relationship between the concentration of ergothioneine in plasma and the likelihood of developing pre-eclampsia. *Biosci Rep* 43.
 53. Yoshida S, H Shime, K Funami, H Takaki, M Matsumoto, et al. (2017) The anti-oxidant ergothioneine augments the immunomodulatory function of tlr agonists by direct action on macrophages. *PLoS One* 12(1): e0169360.
 54. Li A, Y Liu, P Yu, Z Zhang, T Huang, et al. (2025) Ergothioneine attenuates psoriasis symptoms through modulation of m1/m2 macrophage polarisation via the nf-kappab/jak-stat3 pathway. *Front Pharmacol* 16: 1521743.
 55. Mishra A, I J Reddy, A Dhali, P K Javvaji (2018) L-ergothioneine improves the developmental potential of in vitro sheep embryos without influencing octn1-mediated cross-membrane transcript expression. *Zygote* 26: 149-161.
 56. McElwain C J, A Musumeci, S Manna, F P McCarthy, C M McCarthy (2024) L-ergothioneine reduces mitochondrial-driven nlrp3 activation in gestational diabetes mellitus. *J Reprod Immunol* 161: 104171.
 57. Yoshida N, H Murata, K Ide, M Tanaka, K Mori, et al. (2025) Regulatory mechanism of human endometrial stromal cell decidualization by ergothioneine. *Nutraceuticals* 5: 16.
 58. Fujitani Y, K M Alamgir, A Tani (2018) Ergothioneine production using methylobacterium species, yeast, and fungi. *J Biosci Bioeng* 126(6): 715-722.
 59. Dumitrescu D G, E M Gordon, Y Kovalyova, A B Seminara, B Duncan Lowey, et al. (2022) A microbial transporter of the dietary antioxidant ergothioneine. *Cell* 185(24): 4526-4540.
 60. Matsuda Y, N Ozawa, T Shinozaki, K I Wakabayashi, K Suzuki, et al. (2020) Ergothioneine, a metabolite of the gut bacterium *Lactobacillus reuteri*, protects against stress-induced sleep disturbances. *Transl Psychiatry* 10(1): 170.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2025.62.009764

Susumu Tanaka. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>